Celltrion Selected as the Only Korean Company in the Top 1% of S&P ESG Biotechnology Assessment

by Jeong Donghoon

Published 15 Apr.2026 08:46(KST)

Celltrion announced on April 15 that it was selected as a 'Top 1%' company in the Biotechnology sector of the Corporate Sustainability Assessment (CSA) conducted by global credit rating agency S&P Global. In addition, Celltrion was recognized for the largest year-on-year improvement in ESG performance and was also named an 'Industry Mover.'

The CSA is one of the world's most prestigious sustainability assessments, comprehensively evaluating ESG (Environmental, Social, and Governance) performance of more than 12,000 companies worldwide, and selecting top performers by industry. The results are published in The Sustainability Yearbook, with the top 1%, 5%, and 10% companies in each industry being recognized respectively.

Dongjin Lee, Executive Director of Sustainability Management at Celltrion, received a trophy at the award ceremony held at the Westin Chosun Hotel in Seoul. Celltrion

Celltrion, which was included in the global top 5% in the Biotechnology sector last year, has now been ranked in the top 1% this year, demonstrating its leading ESG competitiveness among global biotechnology companies. In particular, Celltrion was also selected as an 'Industry Mover,' an honor given to companies with the largest year-on-year score improvement, acknowledging its significant efforts to advance ESG management.

Celltrion has set forth the vision of 'Establishing a Sustainable Healthcare Service Ecosystem Based on ESG Management' and continues to pursue systematic management activities across all ESG areas.

In the Environmental sector, Celltrion is systematically managing greenhouse gas emissions based on its goal of achieving carbon neutrality by 2045. The company is working to increase the ratio of eco-friendly vehicles to 20% and expand the use of renewable energy. In addition, it is minimizing the environmental impact of its products by expanding Life Cycle Assessment (LCA) to 11 biosimilar products.

In the Social sector, Celltrion is contributing to the development of the domestic bio ecosystem by providing tailored support for startups at each stage of their growth through open innovation activities. The company also continues to support the improvement of medical environments in developing countries such as Madagascar by using proceeds from 'Celeb Market,' an in-house bazaar event where goods donated by employees are sold. Furthermore, through the 'Kkumkureon 2026' campaign, which involved running club members, all participation fees were donated to the Korea Blood Cancer Association, demonstrating Celltrion's commitment to realizing social value as a biotechnology company.

In the Governance sector, Celltrion has introduced a lead independent director system to enhance the independence of its board and is building an advanced governance structure that meets global standards. In terms of shareholder value, Celltrion plans to pay a cash dividend of 750 won per share and retire treasury shares worth 895 billion won in 2025, achieving a shareholder return rate of 103%, the highest level in the industry.

A Celltrion official stated, "Being selected as a 'Top 1%' and 'Industry Mover' in the S&P CSA is a meaningful result that recognizes our ESG management achievements and ongoing improvement efforts in the global market," adding, "We will continue to contribute to the health and welfare of humanity while further strengthening our foundation for sustainable growth."